RH LIF (AF)
Référence 100-47AF-25UG
Conditionnement : 25UG
Marque : FUJIFILM
Recombinant Human LIF
Leukemia inhibitory factor (LIF) is a member of the interleukin 6 (IL-6) family that is made by a variety of adult and embryonic tissues. LIF signals through the glycoprotein 130 (gp130)/LIF receptor (LIFR) heterodimer to activate STAT3 and MAPK signaling. LIF functions during hematopoietic differentiation, neuronal cell differentiation, kidney development, and inflammatory processes. Human LIF may also be an important factor during human embryonic stem cell (hESC) self-renewal, pluripotency, and embryonic implantation.
Product images on the website are not representative of actual product, including, but not limited to differences in cap color, tube type, or label format.
SDS-PAGE Showing a Single Prominent Band at 19.8kDa
Figure 1. rh LIF (1μg) was resolved with SDS-PAGE under non-reducing (NR) conditions and visualized by Instant Blue staining showing a single prominent band at 19.8 kDa
Cell based proliferation assay
Figure 2. Recombinant Human LIF induced proliferation of TF-1 cells
Instructions
Centrifuge vial before opening. Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws.
Technical Specifications
| Alternate Names | Leukocyte Inhibitory Factor |
| Accession Number | P15018 |
| Source | Genetically modified E.coli |
| Predicted Molecular Mass | Monomer, 19.8 kDa (181 aa) |
| AA Sequence | MSPLPITPVN ATCAIRHPCH NNLMNQIRSQ LAQLNGSANA LFILYYTAQG EPFPNNLDKL CGPNVTDFPP FHANGTEKAK LVELYRIVVY LGTSLGNITR DQKILNPSAL SLHSKLNATA DILRGLLSNV LCRLCSKYHV GHVDVTYGPD TSGKDVFQKK KLGCQLLGKY KQIIAVLAQA F |
| Formulation | Lyophilized from a 0.2 µm filtered solution containing 0.1% Trifluoroacetic Acid (TFA) |
| Product Reconstitution | Sterile 10 mM acetic acid at 0.1 mg/mL |
| Country of Origin | USA |
| Specification* | Method of Determination | Acceptance Criteria |
| Purity | Reducing and Non-Reducing SDS PAGE | ≥ 95% |
| Endotoxin | Kinetic LAL | ≤ 0.1 EU/µg |
| Biological Activity (ED50) | TF-1 cell proliferation | ≤ 0.2 ng/mL; ≥ 5.0 x 106 units/mg |
*Lot-specific values for the above specifications are supplied with each product on its corresponding COA. The values provided here are minimum expected values to pass internal requirements.